MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Eli Lilly and Co.

Deschisă

SectorSănătate

868.58 2.23

Rezumat

Modificarea prețului

24h

Curent

Minim

845.8

Maxim

871.37

Indicatori cheie

By Trading Economics

Venit

7.8B

8.8B

Vânzări

2.1B

14B

P/E

Medie Sector

70.036

57.333

EPS

5.32

Randament dividend

0.71

Marjă de profit

65.172

Angajați

47,000

EBITDA

1.2B

6.1B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+16.73% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.71%

2.63%

Următoarele câștiguri

1 mai 2025

Următoarea dată ex-dividende

14 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-50B

735B

Deschiderea anterioară

866.35

Închiderea anterioară

868.58

Scor tehnic

By Trading Central

Încredere

Very Strong Bullish Evidence

Eli Lilly and Co. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

22 apr. 2025, 09:26 UTC

Principalele dinamici ale pieței

Novo Nordisk Shares Fall After Data From New Eli Lilly Pill

18 apr. 2025, 15:57 UTC

Principalele dinamici ale pieței

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

17 apr. 2025, 11:52 UTC

Principalele dinamici ale pieței

Eli Lilly Shares Jump Premarket After First Pill for Diabetes, Weight Loss Shows Positive Study Results

9 apr. 2025, 18:18 UTC

Principalele dinamici ale pieței

Pharma Shares Reverse Losses After Tariff Pause

9 apr. 2025, 09:39 UTC

Principalele dinamici ale pieței

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

4 apr. 2025, 22:38 UTC

Acțiuni populare

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1 apr. 2025, 23:15 UTC

Principalele dinamici ale pieței

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

22 apr. 2025, 09:31 UTC

Acțiuni populare

Stocks to Watch Tuesday: Tesla, Novo Nordisk, Hertz -- WSJ

17 apr. 2025, 18:27 UTC

Top știri

Lilly's First Pill for Diabetes, Weight Loss Shows Positive Study Results -- Update

17 apr. 2025, 10:45 UTC

Top știri

Lilly's First Pill for Diabetes, Weight Loss Shows Positive Study Results -- WSJ

11 apr. 2025, 16:23 UTC

Achiziții, Fuziuni, Preluări

Novo Remade Denmark. Then Came the Stock Selloff. -2-

11 apr. 2025, 16:23 UTC

Achiziții, Fuziuni, Preluări

Novo Remade Denmark. Then Came the Stock Selloff. -- Barrons.com

11 apr. 2025, 09:30 UTC

Top știri

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

11 apr. 2025, 05:00 UTC

Top știri

Wall Street Pulls Back on the Weight-Loss Drug Hype -- Barrons.com

10 apr. 2025, 05:00 UTC

Câștiguri

Amgen Is Getting Into the Obesity Drug Business. Buy the Stock Before It Becomes the Next Winner. -- Barrons.com

8 apr. 2025, 21:26 UTC

Câștiguri

Pfizer Stock's Fall to '97 Level Lifts Yield Near 8%. Dividend Looks Safe. -- Barrons.com

2 apr. 2025, 16:53 UTC

Top știri

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

1 apr. 2025, 22:31 UTC

Top știri

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1 apr. 2025, 21:47 UTC

Top știri

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

19 mar. 2025, 15:54 UTC

Top știri

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

14 mar. 2025, 09:30 UTC

Top știri

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

28 feb. 2025, 12:00 UTC

Top știri

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26 feb. 2025, 15:14 UTC

Top știri

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- Update

26 feb. 2025, 14:30 UTC

Top știri

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- WSJ

10 feb. 2025, 12:00 UTC

Top știri

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7 feb. 2025, 10:30 UTC

Top știri

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 feb. 2025, 16:16 UTC

Top știri
Câștiguri

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6 feb. 2025, 14:56 UTC

Câștiguri

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

6 feb. 2025, 14:32 UTC

Market Talk
Câștiguri

Lilly's Weight-Loss Drug Bonanza Continues -- Market Talk

6 feb. 2025, 13:18 UTC

Top știri
Câștiguri

Eli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ

Comparație

Modificare preț

Eli Lilly and Co. Așteptări

Obiectiv de preț

By TipRanks

16.73% sus

Prognoză pe 12 luni

Medie 1,003.6 USD  16.73%

Maxim 1,124 USD

Minim 888 USD

În baza a 19 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruEli Lilly and Co. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

19 ratings

19

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

732.41 / N/ASuport & Rezistență

Termen scurt

Very Strong Bullish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.